UK asks: which drugs are most at risk of falsification?
This article was originally published in SRA
Executive Summary
Which prescription medicines are least likely to be falsified, and which non-prescription drugs are most at risk? That's what the UK regulator, the Medicines and Healthcare Products Regulatory Agency, would like to know as it prepares to draw up its proposed 'black' and 'white' lists of products that in future either should or should not carry the "safety feature" required by the EU falsified medicines directive (FMD)1.